Gentian Diagnostics ASA (FRA:6FK)

Market Cap	62.19M +0.1%
Revenue (ttm)	14.91M +16.1%
Net Income	1.12M -70.7%
EPS	0.07 -70.1%
Shares Out	n/a
PE Ratio	55.53
Forward PE	17.00
Dividend	0.03 (0.86%)
Ex-Dividend Date	May 7, 2025

Volume	n/a
Average Volume	1
Open	3.980
Previous Close	4.070
Day's Range	3.980 - 3.980
52-Week Range	3.270 - 5.420
Beta	n/a
RSI	63.16
Earnings Date	May 6, 2026

About Gentian Diagnostics ASA

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidne...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2001
• Employees: 64
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6FK

Financial Performance

In 2025, Gentian Diagnostics ASA's revenue was 176.50 million, an increase of 16.07% compared to the previous year's 152.07 million. Earnings were 13.26 million, a decrease of -70.73%.

Financial numbers in NOK